Trial · NCT02159976

Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

NCT02159976, Not applicable, Completed, Seoul National University Bundang Hospital; results first posted 2019-05-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea. Trials, record NCT02159976. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02159976

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
NCT number: NCT02159976
Status: Completed
Phases: Not applicable
Enrollment: 390 participants, actual
Lead sponsor: Seoul National University Bundang Hospital
Conditions: Helicobacter Pylori Infection
Interventions: Pantoprazole, Amoxicillin, Clarithromycin, Metronidazole, Tetracycline, Bismuth
First posted: 2014-06-10
Last updated: 2019-05-13
Results first posted: 2019-05-13

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Counts of Participants With Successful H. Pylori Eradication	4 weeks after termination of eradication therapy, up to 6 weeks
Secondary	Counts of Participants Whose Drug Compliance is More Than 85%	4 weeks after termination of eradication therapy, up to 6 weeks
Secondary	Counts of Participants With Adverse Event	4 weeks after termination of eradication therapy, up to 6 weeks
Secondary	Functional Dyspepsia Symptom Responses Rate	1 year after termination of eradication therapy

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Counts of Participants With Successful H. Pylori Eradication	4 weeks after termination of eradication therapy, up to 6 weeks		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Counts of Participants Whose Drug Compliance is More Than 85%	4 weeks after termination of eradication therapy, up to 6 weeks		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Counts of Participants With Adverse Event	4 weeks after termination of eradication therapy, up to 6 weeks		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Functional Dyspepsia Symptom Responses Rate	1 year after termination of eradication therapy	SQT and PBAT were used for the initial treatment. Thereafter, treatment success and treatment failure group were divided. In the treatment failure group, secondary treatment was performed. Secondary endpoints were functional and dyspepsia symptom responses rate after successful treatment, not success in both treatment groups.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Counts of Participants With Successful H. Pylori Eradication	Sequential Therapy		146	Participants
Counts of Participants With Successful H. Pylori Eradication	Modified Bismuth Quadruple Therapy		134	Participants
Counts of Participants Whose Drug Compliance is More Than 85%	Sequential Therapy		165	Participants
Counts of Participants Whose Drug Compliance is More Than 85%	Modified Bismuth Quadruple Therapy		170	Participants
Counts of Participants With Adverse Event	Sequential Therapy		93	Participants
Counts of Participants With Adverse Event	Modified Bismuth Quadruple Therapy		72	Participants
Functional Dyspepsia Symptom Responses Rate	In Eradication Success Group	complete (≥75%)	44	Participants
Functional Dyspepsia Symptom Responses Rate	In Eradication Failure Group	complete (≥75%)	0	Participants
Functional Dyspepsia Symptom Responses Rate	In Eradication Success Group	Satisfactory (50-74%)	1	Participants
Functional Dyspepsia Symptom Responses Rate	In Eradication Failure Group	Satisfactory (50-74%)	0	Participants

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Sequential Therapy	195
Overall Study	STARTED	Modified Bismuth Quadruple Therapy	195
Overall Study	COMPLETED	Sequential Therapy	165
Overall Study	COMPLETED	Modified Bismuth Quadruple Therapy	170
Overall Study	NOT COMPLETED	Sequential Therapy	30
Overall Study	NOT COMPLETED	Modified Bismuth Quadruple Therapy	25

Source ClinicalTrials.gov

Adverse events30

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Bloating	Gastrointestinal disorders	Sequential Therapy	21	195
other	Bloating	Gastrointestinal disorders	Modified Bismuth Quadruple Therapy	11	195
other	Epigastric soreness	Gastrointestinal disorders	Sequential Therapy	15	195
other	Epigastric soreness	Gastrointestinal disorders	Modified Bismuth Quadruple Therapy	17	195
other	Taste distortions	Gastrointestinal disorders	Sequential Therapy	24	195
other	Taste distortions	Gastrointestinal disorders	Modified Bismuth Quadruple Therapy	4	195
other	Nausea	Gastrointestinal disorders	Sequential Therapy	14	195
other	Nausea	Gastrointestinal disorders	Modified Bismuth Quadruple Therapy	6	195
other	Anorexia	Gastrointestinal disorders	Sequential Therapy	2	195
other	Anorexia	Gastrointestinal disorders	Modified Bismuth Quadruple Therapy	1	195

1 to 10 of 30Source ClinicalTrials.gov

See all 30 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Sequential Therapy
Total, all-cause mortality	Modified Bismuth Quadruple Therapy
Total, other adverse events	Sequential Therapy	93	195
Total, other adverse events	Modified Bismuth Quadruple Therapy	72	195
Total, serious adverse events	Sequential Therapy	0	195
Total, serious adverse events	Modified Bismuth Quadruple Therapy	0	195

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
27460100	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants With Adverse Event	Trial comparisons
Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants With Successful H. Pylori Eradication	Trial comparisons
Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants Whose Drug Compliance is More Than 85%	Trial comparisons
Sequential Therapy vs Modified Bismuth Quadruple Therapy: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02159976

GET https://conductscience.org/api/trials/v1/NCT02159976/events?page=2

API reference For AI assistants